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Background Vaginal brachytherapy is currently 
recommended as adjuvant treatment in patients with high- 
intermediate risk endometrial cancer to maximize local 
control and has only mild side effects and no or limited 
impact on quality of life. However, there is still considerable 
overtreatment and also some undertreatment, which 
may be reduced by tailoring adjuvant treatment to the 
patients’ risk of recurrence based on molecular tumor 
characteristics.
Primary objectives To compare the rates of vaginal 
recurrence in women with high- intermediate risk 
endometrial cancer, treated after surgery with molecular- 
integrated risk profile- based recommendations for either 
observation, vaginal brachytherapy or external pelvic 
beam radiotherapy or with standard adjuvant vaginal 
brachytherapy
Study hypothesis Adjuvant treatment based on a 
molecular- integrated risk profile provides similar local 
control and recurrence- free survival as current standard 
adjuvant brachytherapy in patients with high- intermediate 
risk endometrial cancer, while sparing many patients the 
morbidity of adjuvant treatment and reducing healthcare 
costs.
Trial design A multicenter, international phase III 
randomized trial (2:1) of molecular- integrated risk profile- 
based adjuvant treatment (experimental arm) or adjuvant 
vaginal brachytherapy (standard arm).
Major inclusion/exclusion criteria Women aged 
18 years and over with a histological diagnosis of high- 
intermediate risk endometrioid endometrial cancer after 
total abdominal or laparoscopic hysterectomy and bilateral 
salpingo- oophorectomy. High- intermediate risk factors are 
defined as: (i) International Federation of Gynecology and 
Obstetrics stage IA (with invasion) and grade 3; (ii) stage 
IB grade 1 or 2 with age ≥60 and/or lymph- vascular space 
invasion; (iii) stage IB, grade 3 without lymph- vascular 
space invasion; or (iv) stage II (microscopic and grade 1).
Endpoints The primary endpoint is vaginal recurrence. 
Secondary endpoints are recurrence- free and overall 
survival; pelvic and distant recurrence; 5- year vaginal 
control (including treatment for relapse); adverse events 
and patient- reported symptoms and quality of life; and 
endometrial cancer- related healthcare costs.
Sample size 500 eligible and evaluable patients.
Estimated dates for completing accrual and presenting 
results Estimated date for completing accrual will be late 
2021. Estimated date for presentation of (first) results is 
expected in 2023.
Trial registration The trial is registered at  clinicaltrials. 
gov (NCT03469674) and ISRCTN (11659025).
INTRODUCTION
The cornerstone of treatment for endometrial 
cancer is surgery, consisting of a total abdominal or 
laparoscopic hysterectomy and bilateral salpingo- 
oophorectomy. Based on clinicopathologic risk factors 
such as age, stage, histological type, grade, depth of 
myometrial invasion, and presence of lymph- vascular 
space invasion, patients are considered to be at 
low- to low- intermediate risk (approximately 50% of 
patients), high- intermediate risk (30%–35%), or high 
risk (15%–20%) for disease recurrence (Table  1).1 
Adjuvant treatment has increasingly been tailored to 
these prognostic factors.
Multiple randomized trials have established that in 
stage I endometrial cancer with risk factors, adjuvant 
external pelvic radiotherapy provides a significant 
reduction of vaginal and pelvic recurrence. However 
HIGHLIGHTS
• PORTEC- 4a is the first trial to introduce molecular factors in the adjuvant treatment of endometrial cancer.
• Randomization between standard or individualized treatment based on the molecular risk profile.
• PORTEC- 4a will show if omitting treatment in cases of favorable molecular profiles is safe and cost- effective.
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no overall survival advantage was observed and pelvic radio-
therapy is associated with treatment- related toxicities, predom-
inantly gastrointestinal.2–4 Since most relapses occurred in the 
vaginal vault, the PORTEC-2 trial was initiated to evaluate vaginal 
brachytherapy as compared with pelvic radiotherapy in patients 
with high- intermediate risk endometrial cancer.3–5 The conclusion 
from the PORTEC-2 trial was that vaginal brachytherapy should 
be the adjuvant treatment for patients with high- intermediate risk 
disease because of similar efficacy compared with pelvic radio-
therapy, with lower toxicity and better health- related quality of 
life.5 However, adjuvant brachytherapy of all patients with high- 
intermediate risk features can still be considered overtreatment 
as there are effective salvage treatments for vaginal relapse in 
patients who are not previously irradiated.6 A long- term analysis of 
the PORTEC-2 trial showed that a small subgroup of patients with 
high- risk factors might actually benefit from adjuvant pelvic radio-
therapy to maximize pelvic control. These risk factors are substan-
tial lymph- vascular space invasion, L1- Cell Adhesion Molecule 
(L1- CAM) overexpression, and p53 mutant expression, which are 
all associated with higher risk of both pelvic and distant relapse.6–8
The comprehensive genomic analysis of endometrial cancer by 
The Cancer Genome Atlas (TCGA) has led to important novel insights 
in the genomic landscape of endometrial cancer. The TCGA defined 
four molecular subgroups based on mutational burden and copy 
number alterations. The ultramutated POLE- mutant subgroup is 
characterized by mutations in the exonuclease domain of DNA poly-
merase epsilon and is associated with an excellent prognosis. The 
hypermutated subgroup with microsatellite instability (or mismatch- 
repair deficiency) and the copy- number- low group are both asso-
ciated with an intermediate (stage- dependent) prognosis. The 
copy- number- high group, with highly frequent TP53- mutations, has 
an unfavorable prognosis.9 Several independent groups have devel-
oped and validated surrogate markers for these subgroups that can 
be assessed on paraffin- embedded tissues. A molecular- integrated 
risk model was defined by integrating the molecular subgroups 
with L1- CAM overexpression, substantial lymph- vascular space 
invasion, and CTNNB1- exon 3 mutations.10–12 L1- CAM is an inde-
pendent risk factor of locoregional and distant spread and associ-
ated with TP53- mutations, high tumor grade, and lymph- vascular 
space invasion.12 13 CTNNB1- exon 3 mutations are prognostic 
for higher risk of recurrence, especially in the copy- number- low 
group.11 By applying this molecular- integrated risk profile to the 
high- intermediate risk cohorts of the PORTEC-1 and −2 trials, three 
risk categories (favorable, intermediate, and unfavorable) were 
defined with a significantly different recurrence- free survival.11 It 
is hypothesized that use of this molecular- integrated risk profile 
to determine the adjuvant treatment would reduce overtreatment 
in many patients and reduce undertreatment in a small propor-
tion, with similar vaginal control and recurrence- free survival. The 
PORTEC- 4a trial is the first study worldwide to evaluate the clinical 
role of molecular risk factors in decision making on adjuvant treat-
ment in patients with endometrial cancer.
METHODS
Trial design
The PORTEC- 4a trial is a prospective, multicenter phase III 
study, led by the Dutch Gynaecologic Oncology Group. A total of 
500 eligible and evaluable women with high- intermediate risk 
Table 1 Risk groups of endometrial cancer and current treatment recommendations
Risk group ESMO- ESGO- ESTRO consensus1 Common treatment recommendations
Low risk Stage I EEC, grade 1–2,<50% 
myometrial invasion, LVSI negative
No adjuvant treatment
Low- intermediate risk Stage I EEC, grade 1–2,≥50% 
myometrial invasion, LVSI negative
Vaginal brachytherapy
(consider observation if age <60 years)
High- intermediate risk Stage I EEC, grade 3,
<50% myometrial invasion, any LVSI
Stage I EEC, grade 1–2,
LVSI unequivocally positive, any 
myometrial invasion
Vaginal brachytherapy
Consider pelvic external beam radiotherapy if LVSI is unequivocally 
positive, especially if no lymph node dissection or sentinel node has 
been performed.
High risk Stage I EEC, grade 3,
≥50% myometrial invasion, any LVSI
External beam radiotherapy
Consider vaginal brachytherapy if no LVSI
Stage II EEC
Stage III EEC
Vaginal brachytherapy if grade 1–2 and LVSI negative
Pelvic radiotherapy if :
 ► Stage II, grade 3
 ► LVSI unequivocally positive
 ► Stage III
Stage III: combined adjuvant radiotherapy and chemotherapy 
(PORTEC-3 schedule or sequential)
NEEC stage I–III (serous, clear 
cell or undifferentiated cancers; 
carcinosarcoma)
Vaginal brachytherapy if serous/clear cell, stage IA after full surgical 
staging, LVSI negative
Stage IB–III: combined adjuvant pelvic radiotherapy and 
chemotherapy
EEC, endometrioid endometrial cancer; ESGO, European Society of Gynecological Oncology; ESMO, European Society for Medical 
Oncology; ESTRO, European Society; LVSI, lymph- vascular space invasion; NEEC, non- endometrioid endometrial cancer; PORTEC, 
post operative radiation therapy endometrial cancer.
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endometrioid endometrial cancer will be randomized (2:1) to the 
experimental arm with molecular- integrated risk profile- based 
adjuvant treatment: observation in case of a favorable risk profile, 
vaginal brachytherapy in case of intermediate risk, and pelvic radi-
otherapy in case of an unfavorable risk profile; or to the standard 
arm with adjuvant vaginal brachytherapy. After informed consent 
and randomization, histopathological slides and a representative 
tumor tissue block are sent for expert gynecopathology review and 
determination of the molecular- integrated risk profile. Microscopy 
is used to confirm histological type, grade and invasion, and, espe-
cially, evaluation and semi- quantification of lymph- vascular space 
invasion. Immunohistochemistry is needed to determine L1- CAM, 
p53, and mismatch- repair protein expression (MLH1, PMS2, MSH2, 
and MSH6). Pathogenic POLE- mutations and CTNBB1- exon 3 status 
are determined by DNA sequencing. In a small subgroup (3%–6%) 
of cases the tumor will have more than one classifying feature 
(combinations of POLE-mutations, mismatch- repair deficiency, and 
p53- abnormal staining).14 Risk profiles for these so- called ‘multiple 
classifiers’ are assigned as follows, based on a previous extensive 
analysis: favorable in case of a POLE- mutation irrespective of other 
classifiers; intermediate if both mismatch- repair deficiency and 
p53 abnormal staining, but unfavorable if also substantial lymph- 
vascular space invasion or L1- CAM overexpression is found.In any 
other case the least favorable factor will determine the risk profile 
(see Figure 1).14
In each participating country, at least one pathology laboratory 
has been validated for review and determination of the molecular- 
integrated risk profile.
Based on previous analysis it is expected that approximately 
50%–55% of patients with high- intermediate risk endometrial 
cancer have a favorable molecular profile.11 In the experimental 
arm this subgroup will receive no adjuvant treatment and will be 
observed. An estimated 40% of patients have an intermediate 
profile and will receive vaginal brachytherapy (21 Gy in three 
fractions of 7 Gy each within an overall time of 2 weeks). About 
5%–10% will have an unfavorable profile and receive pelvic radio-
therapy (45–48.6 Gy in 1.8–2 Gy fractions) (see Figure 1).11 Patients 
are clinically evaluated during alternating follow- up visits to their 
gynecologist and radiation oncologist every 3 months for the first 3 
years for early detection of local recurrence, and at 6- month inter-
vals until 5 years. For long- term information, vital status and events 
are also recorded at 7 years. Toxicity is evaluated using Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.0. and 
patient- reported health- related quality of life is evaluated using 
the European Organization for Research and Treatment of Cancer 
Quality- of- life Questionnaire Core 30 questionnaire (EORTC QlQ- 
C30)and the endometrial cancer- specific module (EN24). In case 
of (suspected) recurrence or metastasis, full evaluation is required 
and treatment with curative intention is initiated if appropriate.
Currently, a total of 22 sites in Belgium, Czech Republic, Germany, 
France, Ireland, and The Netherlands are open for inclusion and 
another eight are preparing for participation. The study is supported 
by the Dutch Cancer Society (UL2011-5336 and UL20).
Participants
Patients aged 18 years or older with a WHO performance status 
of 0–2 with a histological diagnosis of endometrioid endometrial 
cancer with high- intermediate risk features (as listed in Box 1) are 
eligible after surgery, consisting of a total abdominal or laparoscopic 
hysterectomy and bilateral salpingo- oophorectomy. Lymphadenec-
tomy, lymph node sampling, or sentinel node procedure are not 
required but permitted as per center standard protocol.
Patients diagnosed with malignancy (except for non- melanoma 
skin cancer) in the past 5 years and/or previous pelvic radiotherapy 
are excluded. In addition, patients are not eligible if the interval 
between date of surgery and start of radiotherapy is expected to 
exceed 8 weeks.
Figure 1 Study design PORTEC- 4a trial. Reprinted from 'Molecular- integrated risk profile to determine adjuvant radiotherapy 
in endometrial cancer: evaluation of the pilot phase of the PORTEC- 4a trial' by Wortman et al., 2018, Gynecologic Oncology 
151; 69–75. A: trial design of the PORTEC- 4a trial; B: decision tree for the molecular- integrated profile; CTNNB1, β-catenin; 
EBRT, external beam radiotherapy; LVSI; lymph- vascular space invasion; HIR, high- intermediate risk; L1- CAM, L1- cell adhesion 
molecule; POLE, polymerase-ɛ * stage I (with invasion) disease, grade 3 tumor; stage IB disease, grade 1 or 2 tumor, with either 
age 60 years or older or substantial LVSI; stage IB disease, grade 3 tumor, without LVSI; or stage II (microscopic) disease, 
grade 1 tumor.
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Primary and secondary endpoints
The primary endpoint is vaginal recurrence. Secondary endpoints 
are 5- year recurrence- free and overall survival; vaginal control 
(including treatment for relapse); pelvic and distant recurrence; 
adverse events; patient- reported symptoms and health- related 
quality of life; and endometrial cancer- related healthcare costs.
Translational research is an integral part of this molecular- 
integrated risk profile- based trial. Therefore, a tumor tissue block 
of all patients is collected and stored in the dedicated tissue bank 
at Leiden University Medical Center for further analysis.
Randomization
The study is an open- label phase III trial with (2:1) randomized allo-
cation to either molecular- integrated risk profile- directed adjuvant 
treatment (experimental arm) or adjuvant vaginal brachytherapy 
(standard arm). Central randomization is done by a web- based 
randomization application with stratification for participating center, 
tumor grade (1 vs 2 vs 3), and type of surgery (lymphadenectomy 
yes or no) using a biased coin minimization procedure. The trial 
number and result of randomization are immediately obtained via 
the randomization system and confirmed by email.
Sample size
It is hypothesized that the experimental treatment strategy leads to 
less overtreatment, which would yield less morbidity and a better 
quality of life. As treatment will be deescalated in a substantial part 
of the patients in the experimental arm, a non- inferiority design 
was chosen to estimate vaginal recurrence in both groups with 
sufficient precision and to exclude a clinically relevant difference 
with an equivalence margin of 7%. Other first recurrences (pelvic 
and distant) and death are considered competing risks. Based on 
data from the PORTEC-2 trial and the molecular analysis from the 
pooled PORTEC-1 and 2 trials, the expected 5- year rates of vaginal 
recurrence are 2.0% in the vaginal brachytherapy arm and 4.625% 
in the molecular profile arm. The null hypothesis states that the 
5- year cumulative incidence of vaginal recurrence in the molecular 
profile- directed treatment arm exceeds that of the standard vaginal 
brachytherapy arm by more than an equivalence margin of 7%: 
the null hypothesis will be rejected if the upper bound of the one- 
sided 95% Wald confidence interval of the difference (molecular 
arm minus standard arm) does not exceed the equivalence margin. 
The inclusion period was estimated to be 4 years, with a follow- up 
period of 3 years after inclusion of the last patient. For a total of 500 
evaluable patients, with 167 patients in the standard arm and 334 
in the molecular arm, a power of 84.4% is achieved. An additional 
power calculation was performed for a subgroup analysis among 
all patients with a favorable risk profile to determine the difference 
in vaginal recurrence between the experimental group (no adju-
vant treatment) and the standard treatment group (brachytherapy). 
These groups will be compared using a non- inferiority design 
with an equivalence margin of 8.5%. The power will depend on 
the actual difference between the arms. For example, if the 5- year 
cumulative incidence of vaginal recurrence would be 4% in the 
experimental arm and 1.5% in the standard arm, the power will be 
89.7%: for 5% vs 1.5% this would be 75%. The main aim of this 
analysis is to estimate the difference in vaginal recurrence in the 
favorable subgroups with sufficient precision (SE of the difference 
below 2.4%).
The pilot phase (first 50 patients) of the PORTEC- 4a trial has 
been completed and showed that the trial design is acceptable for 
patients and feasible in terms of the logistics for determining the 
molecular profile within 2 weeks.13 Currently, 366 patients have 
been included. Monitoring of safety is done by the Data and Safety 
Monitoring Board. Annual safety reviews of serious adverse events, 
deaths, and recurrences are presented confidentially to the Data 
and Safety Monitoring Board, which is free in its recommendations 
to the study coordinators and confidential recommendations to the 
study statistician.
Statistical methods
All analyses concerning treatment effects will be performed 
according to the intention- to- treat principle. Time- to- event 
analyzes will be performed with date of randomization as a starting 
point. Formal tests for the differences in relapse and survival rates 
between the two arms will be done with the Kaplan–Meier method, 
the log- rank test, and Cox regression analysis. The competing risk 
method will be used, with competing risks of death, pelvic recur-
rence, and distant recurrence for analysis of vaginal recurrence, 
and competing risk of death for analyses of pelvic and distant 
recurrence. Analysis of toxicity will be based on treatment received. 
P- values<0.05 will be considered statistically significant.
For the cost- utility analysis, endometrial cancer- related health-
care costs will be considered. This includes in both arms of the 
trial the costs of: primary treatment, care associated with adverse 
events, and first treatment for relapse and/or metastasis. Health-
care use across the follow- up period will be converted to costs 
using standard prices, discounted over time. The difference in 
quality- adjusted life years and costs between the two arms will be 
compared according to the intention- to- treat principle, using t- tests 
with, if appropriate, multiple imputation of missing data.
Box 1 Inclusion and exclusion criteria of the PORTEC- 4a 
trial
Inclusion criteria*
• Women aged 18 years and over
• Surgery consisting of a total abdominal or laparoscopic hysterecto-
my and bilateral salpingo- oophorectomy
• Endometroid endometrial cancer with high- intermediate risk 
features:
 – Stage IA (with invasion), grade 3 (any age, with or without 
lymph- vascular space invasion)
 – Stage IB, grade 1 or 2 and age >60 years
 – Stage IB, grade 1 or 2 with documented lymph- vascular space 
invasion
 – Stage IB, grade 3 without lymph- vascular space invasion
• Stage II (microscopic), grade 1
• Treatment with curative intent
Exclusion criteria
• Any diagnosis of malignancy <5 years ago (except non- melanoma 
skin cancer)
• Previous pelvic radiotherapy
• WHO performance status 3–4
• Expected interval between surgery and start of adjuvant treatment 
exceeding 8 weeks
*International Federation of Gynecology and Obstetrics stage
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Health- related quality of life analysis will be performed for 
patients with a valid baseline measurement and at least one 
follow- up measurement. To evaluate the differences between the 
treatment groups with respect to the effect of treatment burden on 
life quality during and up to 5 years after treatment, the repeated 
measures of the scales of the quality of life questionnaires will be 
analyzed using mixed ANOVA models. Single items will be analyzed 
using logistic regression at different timepoints.
DISCUSSION
Several randomized trials, such as the GOG-99, ASTEC, and 
PORTEC-1 and −2 trials, have established recommendations 
for the adjuvant treatment of endometrial cancer based on clin-
icopathological risk factors.2–5 Current international guidelines 
recommend adjuvant vaginal brachytherapy for women with early 
stage high- intermediate risk endometrial cancer, while those with 
low- and low- intermediate risk disease are recommended to be 
observed after surgery.1–5 The molecular classification of endome-
trial cancer, as first defined by TCGA and subsequently validated 
by the use of surrogate markers which makes the molecular tests 
available in daily clinical practice, has profoundly altered the risk 
classification. The PORTEC- 4a trial is the first randomized trial 
to implement the use of molecular factors to determine adjuvant 
treatment. The molecular- integrated risk profile includes both the 
molecular groups and other essential risk factors such as substan-
tial lymph- vascular space invasion and L1- CAM overexpression.7 12 
The PORTEC- 4a trial will provide essential information on whether 
vaginal brachytherapy can be safely omitted in patients with a 
favorable molecular- integrated risk profile, and whether patients 
with an unfavorable risk profile would benefit from more intensive 
adjuvant treatment. If local control rates in the molecular- integrated 
risk profile- directed adjuvant treatment arm are not significantly 
worse than in the standard arm, then patients will have the benefit 
of less overtreatment, with an expected substantial reduction in 
morbidity and a better quality of life.
The acceptance and implementation of the molecular- integrated 
risk profile in standard care will be facilitated if the cost- utility 
analysis shows that molecular- integrated risk profile- tailored adju-
vant treatment leads to similar or even reduced healthcare costs. 
Even though the costs in the experimental group will be higher 
due to determination of the molecular- integrated risk profile by 
next- generation sequencing, about 50%–55% of the patients with 
a favorable profile will receive no adjuvant treatment which will 
substantially reduce costs. However, the costs of any additional 
recurrence in the experimental arm may partially counterbalance 
this effect. In addition, it is expected that a substantial reduction in 
the cost of the molecular profile will be realized as cheaper targeted 
POLE sequencing methods are being developed.
During the trial both national and international pathology labo-
ratories are being validated for determination of the molecular- 
integrated risk profile, leading to early and rapid dissemination and 
optimization of the molecular techniques and logistical processes. 
If cost- utility is confirmed, it is expected that molecular- integrated 
risk profile- directed adjuvant treatment will rapidly be accepted 
as the standard approach in clinical practice and used in future 
studies.
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